Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
BIOCEPT INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
- Exchange
- nasdaq
- Notice
- deficiency notice
- Deficiency
- stockholders equity
- Rules
- 5550(b)(1)
Exact text from the filing
May 17, 2023, Staff also notified the Company that it failed to maintain a minimum of $2,500,000 in stockholders’ equity required for continued listing pursuant to Listing Rule 5550(b)(1), which deficiency serves as an additional and separate basis for delisting. The Staff letter indicates that the trading of the Company’s common stock and warrants will be suspended at the opening of business on October 25, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. The Company does not i
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
BIOCEPT INC received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).
- Exchange
- nasdaq
- Notice
- delisting notice
- Rules
- 5101, 5110(b), IM-5101-1
Exact text from the filing
October 16, 2023, the Company received a letter (“Delisting Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff had determined that the Company’s securities will be delisted from Nasdaq pursuant to Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, in connection with the filing of a voluntary case under Chapter 7 of Title 11 of the United States Bankruptcy Code, 11 U.S.C. §§ 101 et seq. (the “Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) on October 13, 202
View on SEC.gov